Tumor immune microenvironment changes by multiplex immunofluorescence staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a hereditary BRCA mutation - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35736816/
Purpose The immunological profile of early-stage breast cancer treated with neoadjuvant PARP inhibitors has not been described. The aim of this study was to delineate the changes in the tumor...
Conclusion: These findings support an emerging role for PARP inhibitors in enhancing tumor immunogenicity. Further investigation of combinatorial strategies is warranted with agents that exploit the immunomodulatory effects of PARP inhibitors on the TiME.
Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer
Source : https://www.tandfonline.com/doi/abs/10.1080/14737140.2022.2093719?journalCode=iery20
Abstract The majority of the over 250,000 new cases of invasive breast cancer diagnosed in the United States is driven by hormone receptor signaling (HR+). Since 2015, cyclin-dependent kinase 4...
Relevance: Herein, we discuss the data, the population studied and the population in which abemaciclib is approved as well as safety, tolerability, and dose reductions for practical management of these patients.
VERONICA: Randomized Phase 2 Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, Biomarker Results - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35583555/
doi: 10.1158/1078-0432.CCR-21-3811. Online ahead of print. 1 Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 2 Genentech, South San Francisco, CA, United States. 3 Royal United Hospital, United Kingdom. 4 Sunnybrook...
Conclusions: Our findings do not indicate clinical utility for venetoclax plus fulvestrant in endocrine therapy-resistant, CDK4/6 inhibitor-refractory metastatic breast tumors, but suggest possible increased dependence on BCLXL in this setting.
-
Albert Dekker4yrand who thought it would?
Construction and investigation of circRNA-associated ceRNA regulatory network in molecular subtypes of breast cancer.
Source : https://www.eurekaselect.com/article/124500
Background: Circular RNAs (circRNAs) act as competing endogenous RNAs (ceRNAs) that indirectly regulate gene expression and function by binding microRNAs (miRNAs). A growing body of evidence indicates that the ceRNA...
Conclusion: The current study provides a potential application of ceRNA network within BC subtypes, and may offer new targets for their diagnosis, therapy and prognosis.
Cyclin-Dependent Kinase 4/6 Inhibitors Against Breast Cancer
Source : https://www.eurekaselect.com/article/124195
Breast cancer is the most frequently diagnosed and leading cause of cancer-related deaths in women worldwide. Based on global cancer (GLOBOCAN) 2020 statistics, 1 in 4 cancer cases and 1...
Relevance: In this review, we highlight these CDK4/6 inhibitor compounds with potent anti-CDK4/6, in vitro and in vivo activities on breast cancer cells. With the remarkable prospects of these compounds, there is great optimism further novel CDK inhibitor compounds will be discovered in the future that could boost therapeutic options for cancer...